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Abstract
Background: Pertussis remain a global health concern, especially in infants too young to initiate their vaccination.
Effective vaccination and high coverage limit the circulation of the pathogen, yet duration of protection is limited
and boosters are recommended during a lifetime. In Iran, boosters are given at 18 months and 6 years old using
whole pertussis vaccines for which efficacy is not known, and pertussis surveillance is scant with only sporadic
biological diagnosis. Burden of pertussis is not well understood and local data are needed.
Methods: Hospital-based prospective study implementing molecular laboratory testing in infants aged ≤6 months
and presenting ≥5 days of cough associated to one pertussis-like symptom in Tehran. Household and non-
household contact cases of positive infants were evaluated by comprehensive pertussis diagnosis (molecular testing
and serology) regardless of clinical signs. Clinical evaluation and source of infection were described.
Results: A total of 247 infants and 130 contact cases were enrolled. Pertussis diagnosis result was obtained for 199
infants and 104 contact cases. Infant population was mostly < 3 months old (79.9%; 157/199) and unvaccinated
(62.3%; 124/199), 20.1% (40/199) of them were confirmed having B. pertussis infection. Greater cough duration and
lymphocyte counts were the only symptoms associated to positivity. Half of the contact cases (51.0%; 53/104) had a
B. pertussis infection, median age was 31 years old. A proportion of 28.3% (15/53) positive contacts did not report
any symptom. However, 67.9% (36/53) and 3.8% (2/53) of them reported cough at inclusion or during the study,
including 20.8% (11/53) who started coughing ≥7 days before infant cough onset. Overall, only five samples were
successfully cultured.
Conclusion: These data evidenced the significant prevalence of pertussis infection among paucy or poorly
symptomatic contacts of infants with pertussis infection. Widespread usage of molecular testing should be
implemented to identify B. pertussis infections.
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Introduction
Pertussis (whooping cough) is a highly contagious re-
spiratory disease caused by Bordetella pertussis or, in a
lower extent, Bordetella parapertussis, typically transmit-
ted through airborne droplets. Vaccines have been devel-
oped since 1940s and are now used globally, including in
Low and Middle-Income Countries (LMIC) since the in-
ception Expanded Programme on Immunization in
1974. Mass vaccination led to an important decrease in
pertussis incidence, however, the pathogen still circu-
lates worldwide even in countries where vaccine cover-
age is high in infants and young children. It remains an
important cause of morbidity and mortality among in-
fants too young to have initiated their primary vaccine
series, who account for the majority of pertussis related
complications, hospitalizations and deaths. Yeung and
colleagues estimated that around 24.1 million cases and
160,700 deaths from pertussis in children younger than
5 years occurred in 2014; 21% cases and 53% of deaths
being attributed to children less than 1 year of age [1].
To limit the period of vulnerability for infants, the
World Health Organization (WHO) recommends to ini-
tiate the pertussis vaccination at 6 weeks of age and no
later than 8 weeks, and maintain high coverage (≥90%)
with at least three doses of quality assured pertussis vac-
cine [2, 3].
Modeling studies showed that LMIC contribute for
the largest share of pertussis cases and deaths, however
accurate data are limited in those countries [4]. In
addition, LMIC use whole-cell vaccines (wPVs) for
which immunogenicity and efficacy have not been ana-
lyzed. The various wPVs manufactured in the past and
largely studied in the 1990s in high-income countries
(HIC), where acellular vaccines (aPVs) are now mostly
used, exhibited efficacy variability, which raises the ques-
tion of the contemporary wPV effectiveness. It is thus
necessary to gather information on pertussis epidemi-
ology in those countries.
The pertussis vaccination program in Iran includes a
3-dose primary vaccination at 2, 4 and 6months of life,
and two additional doses at 18 months and 5–6 years of
life with wPVs mainly provided by the Serum Institute
of India. Based on WHO and United Nations Children’s
Fund (UNICEF) estimates, vaccine coverage ≥95% for
1st and 3rd dose is maintained since the early 1990s,
when number of cases dropped down [5, 6]. Still, pertus-
sis cases are reported every year and we observed an in-
creasing notification since 2007 [6]. Pertussis Reference
Laboratory in Tehran has been isolating clinical pertussis
strains from samples from different part of the country
but number of samples only represent a small part of
the notified cases [7, 8]. Studies using most recent sensi-
tive technology is limited but available data showed that,
as observed elsewhere, infants younger than 1 year of
age had the highest pertussis incidence in Iran, and the
circulation of the pathogen has been documented among
older children and adolescents [9–11]. Yet, burden of
pertussis is unclear in Iran and clinical and biological
surveillance remain scarce.
This study aimed at improving our knowledge of per-
tussis in infants with whooping cough syndrome in
Tehran, Iran, and at better understanding the source of
infection by analyzing the close contacts of infected
infants.
Methods
Study population and design
This hospital-based prospective study was conducted in
Tehran, Iran, from November 2016 to May 2019. Infants
were recruited at the Mofid Children’s Hospital (site 1) and
Hazrat-e-Ali Asghar Hospital (site 2). Male and female in-
fants were eligible for enrollment as index case if they were
being aged ≤6months, either with a persistent cough for at
least 5 days associated to at least one symptom among
apnea, inspiratory “whooping”, or post coughing vomiting,
or with a persistent cough and a confirmed case of whoop-
ing cough in the entourage. Upon enrollment of index case,
two nasopharyngeal samples were collected, and data on
age, sex, size and weight, birth information, pertussis vac-
cination history, type and duration of pertussis-related
symptoms, biological test results, antibiotic treatment type
and duration, previous consultation, family composition
and case of cough in the entourage, animal contact, were
collected. Follow-up on pertussis-related symptoms, anti-
biotic treatment, hospitalization and disease outcome was
performed at day 7 and 14 after inclusion.
For each PCR-positive index case, up to five contact
cases, living or not in the same household, were re-
cruited within 14 days from respective index case inclu-
sion. Inclusion criterion was having had a regular
contact (> 1 h/day) with the index case for at least 5 days
before symptom onset in the infant. Upon enrollment of
contact case, two nasopharyngeal samples and one capil-
lary blood sample were collected, and data on age, gender,
relationship with index, pertussis vaccination history, type
and duration of past and current pertussis-related symp-
toms, antibiotic treatment type and duration and previous
consultation were collected. Follow-up on cough duration,
antibiotic treatment and disease outcome was performed
at day 7 and, in case of pertussis infection confirmation,
day 14 after inclusion.
Data were collected in standardized paper question-
naires and recorded in a computerized database.
Biological sample collection and analysis
All the sampling material and laboratory reagents were
provided by Institut Pasteur, Paris, and shipped to the
Institut Pasteur of Iran.
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Samples were collected by nurses in a standardized
manner across study sites. Two nasopharyngeal samples
were collected for each participant using Eswab contain-
ing Amies transport medium (Dacron, Ref. 482 CE). In
contact cases, one blood sample (200–400 μl) was also
collected in SST microtainer tubes from the tip of a
finger using a lancet 23G needle (Becton Dickinson, Ref.
365,968 and 369,523, respectively). Nasopharyngeal and
serum samples were stored at 15–25 °C and sent within
6 h to the Bacteriology Laboratory at the Institut Pasteur
of Iran in Tehran.
Quantity controls were blindly tested before initiating
the study and the principle of the walking forward logic
for PCR analysis was employed to ensure quality of the
result.
Real-time quantitative polymerase chain reaction (qPCR)
analysis and bacterial culture for direct diagnosis
Upon reception by the laboratory, nasopharyngeal sam-
ples were kept at 4 °C. One nasopharyngeal sample was
used for qPCR analysis, the other one for culture.
For qPCR analysis, DNA extraction was performed
within 48 h. When not possible, sample was stored at −
20 °C until processing. Nasopharyngeal sample was
homogenized by vortex and swab was discarded. Total
DNA was extracted from 100 μl of the transport media
(pure sample) and from 10 μl of the transport media
spiked into 90 μl of sterile water (diluted sample), using
the commercial High Pure PCR Template preparation
kit (Roche). For each sample, both pure and diluted
DNA extract solutions were tested by qPCR to address
possible PCR inhibition. qPCR were carried-out using
the commercial LightCycler 480 Probes Master kit
(Roche), forward and reverse primers 0.5 μM and Taq-
man probe 0.2 μM (TIB Molbiol), DMSO 2.5% (Sigma),
and 5 μl of DNA extract solution. Amplification of inser-
tion elements IS481 (Bordetella spp.) and IS1001 (B.
parapertussis) was first assessed [12–14]. IS481 qPCR is
very sensitive but not specific as it targets DNA of both
B. pertussis and B. holmesii [15]. Thus, IS481+ samples
were tested for ptxp, IS1002 and hIS1001 amplification
to identify B. pertussis (ptxp + and/or IS1002+) and B.
holmesii (hIS1001+) (see Additional file 1). Primers and
probes were published elsewhere and are listed in
Additional file 2 [14]. qPCR analyses were carried out
using the Light Cycler 96 Instrument (Roche). Sequence
of rnasep human gene was amplified to ascertain quality
of sampling and laboratory procedures. Purified DNA
from Bordetella reference strains and non-template con-
trol samples (PCR-grade water) were included as positive
and negative qPCR control samples, respectively, in each
qPCR run.
Quality control samples and B. pertussis, B. paraper-
tussis, and B. holmesii positive control samples were
kindly given by the National Reference Centre of whoop-
ing cough and other Bordetella diseases, Institut Pasteur,
Paris.
For culture, nasopharyngeal swab was streaked on
fresh Bordet Gengou mediums (Difco, USA) containing
10% defibrinated horse blood with and without cepha-
lexin (40 μg/mL) (Sigma Chemical Co., USA). After
incubation, suspected colonies were confirmed as B. per-
tussis or B. parapertussis using qPCR targeting ptxp and
IS481, and IS1001 sequences, as previously described,
respectively.
Serology analysis for indirect diagnosis
Upon reception by the laboratory, blood was immedi-
ately spun, and serum was stored at − 20 °C for later
analysis. Quantitative assessment of anti-pertussis toxin
(PT) immunoglobulin G (IgG) was performed using a
purified PT-containing Enzyme-linked immunosorbent
assay (ELISA) kit (EUROIMMUN, Ref. EI 2050-G) [16],
and the WHO reference serum available from the
National Institute for Biological Standards and Control
(NIBSC). Results were given in International Units (IU)/
ml. Lower limit of quantitation (LLOQ) was defined as
5 IU/ml.
For indirect diagnosis, a cut-off was set at 100 IU of
anti-PT IgG titers to define a B. pertussis positive con-
tact, at one-year distance from a planned immunization
as recommended by National schedule.
Definition of Bordetella pertussis case
Full-range cycle threshold (CT) value was considered for
IS481+ qPCR [17]. Among IS481+ sample, B. pertussis
species was molecularly confirmed with IS1002+ and/or
ptxp+, and/or epidemiologically when B. pertussis
species was confirmed in at least one contact case by
serology or by qPCR (see Additional file 1). B. pertussis
infection could not be confirmed for all IS481+ biological
samples, those samples were excluded for analysis.
Definition of source of infection
Identification of potential source of infection of index
cases was performed based on date of cough onset of
symptomatic contact and relative index cases, as re-
ported at inclusion or during clinical follow-up. A con-
tact was classified as primary case if he/she started
coughing ≥7 days before the index cough onset, and was
coughing for ≥12 days. A contact was classified as
secondary case if he/she started coughing 1 to 6 days be-
fore, the same day, or after the index cough onset.
Timeliness of pertussis immunization
Timeliness of primary vaccination schedule in infants
was analyzed based on the national recommendations.
Definition used was the following: having received the
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1st dose at 2 months +/− 14 days, and the 2nd and
3rd doses at 4 to 10 weeks interval from the previous
dose [10].
Statistical analyses
Anthropometric z-scores (wasting as weight-for-height,
stunting as height-for-age) were calculated and inter-
preted using the 2006 WHO child growth standards
[18]. For continuous variables, medians, interquartile
ranges (IQR), minimums and maximums were calcu-
lated. Comparisons were carried out using a Student test
or a non-parametric Wilcoxon test. When necessary,
continuous variables were categorized based on median
values or values commonly acknowledged in the litera-
ture. Spearman’s coefficient was used to assess rank
correlation. For categorical variables, averages were cal-
culated, and comparisons were carried out using the
two-sided Chi2 or Fisher’s Exact test. To control the
confounding factors and to identify the risk factors
associated with pertussis infection, a logistic regression
analysis was performed. Hematological test results were
considered if performed within 4 days from inclusion
date. Denominators may differ across analyses due to
missing information in questionnaires. Differences were
considered significant at p < 0.05.
Results
Study population
A total of 247 infants were enrolled over a period of 31
months (Fig. 1a). Twenty-six infants were subsequently
excluded due to screening failure and one due to qPCR
analysis failure. Biological analyses were performed for
the 220 remaining infants. All infants lived in Tehran
province.
A total of 130 contacts of qPCR-positive index cases
were enrolled (Fig. 1b). Six contacts were excluded due
to relative index case exclusion, 18 were excluded due to
the absence, poor quality (hemolysis) or low amount of
serum samples. Biological analyses were performed using
information from 106 individuals who were contact
cases of 39 qPCR-positive index cases.
Index cases
Pertussis diagnosis
Final diagnosis was obtained for 199/220 infants. For 21/
220 infants exhibiting IS481 CT value > 35, B. pertussis
infection could not be confirmed, these infants were ex-
cluded from analysis. A total of 40/199 (20.1%) infants
were confirmed to have a B. pertussis infection (Table 1).
Similar positivity rates were observed in sites 1 and 2,
with 18.1 and 21.6% of B. pertussis positive infants, re-
spectively (p = 0.55). Only 4/40 B. pertussis were isolated,
including 1 co-infected with B. parapertussis. No B. hol-
mesii was either detected by qPCR or isolated among
those cases.
Pertussis immunization history
Median age of infants was 2 months and ranged from 8
days to 6 months (Table 1). Distribution of age was simi-
lar among positive and negative infants with 79.9% who
were less than 3 months old (Table 1). As expected,
there was a strong positive correlation between the
number of vaccine doses an infant had received and his/
her age (rs = 0.8091; p < 0,001). Most infants were unvac-
cinated (124/199; 62.3%), including 4 who were 2.5 to
5.2 months old and thus already above the higher limit
of age in Iran for dose 1 injection (defined as 75 days).
There was 73/199 (36.7%) vaccinated infants, mostly
with one dose only (58/73). Compliance with recom-
mended age for dose 1 injection was 95.8, and 100% of
infants who had more than one dose complied with sub-
sequent dose intervals.
Among B. pertussis positive index cases, 1/40 infants
was fully and timely vaccinated as recommended by
National schedule; third vaccine injection was achieved
12 days before nasopharyngeal sampling.
Fig. 1 Flow chart of index (a) and contact (b) cases included in the analysis
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Clinical assessment
Respiratory symptoms and biological information were
analyzed and compared among confirmed B. pertussis
positive and negative index cases (Table 2). Median dur-
ation of cough at the time of enrollment was 8 days with
82.9% of infants reporting less than 14 days of cough.
Duration was significantly longer among B. pertussis
positive as compared to negative index cases. Coughing
spells (81.9%), good condition between cough (70.6%),
cyanosis (65.3%), and nocturnal cough (52.3%) were
those most frequently observed. None of the symptoms
was significantly associated to biological diagnosis.
Abnormal pulmonary auscultation and temperature
were rarely observed (13.5 and 4.5%, respectively).
Hematological analysis evidenced that leukocyte and
lymphocyte counts were significantly higher among
positive children as compared to those tested negative
(p < 0.001 for both), and absolute hyper lymphocytosis
was observed in 54.3% of the B. pertussis positive infants
and 18.8% of the negative infants. Prematurity, low birth
weight and scores associated to malnutrition were not
associated to pertussis diagnosis. An antibiotic therapy
had already been given to 63.8% of the infants before en-
rollment in the study. Macrolide treatment was used by
43.6% of infants, including by 16/40 of those tested posi-
tive for pertussis. Most of the infant enrolled were hospi-
talized (95.5%).
Two deaths occurred during the study. One of these
two infants was an unvaccinated 1-month-old infant who
was confirmed positive for pertussis infection and had
hyperlymphocytosis. The second infant who was diag-
nosed negative for pertussis had no hyper lymphocytosis,
no information was reported regarding possible diagnosis.
Both cases had temperature 38 °C and 38.5 °C, respect-
ively, and had coughed for 7 days at the moment of death.
Contact cases
A median of 3 contact cases were enrolled per index case,
and numbers ranged from 1 to 5. There were fathers and
mothers (71/106), siblings (22/106), grandfathers and
grandmothers (8/106), uncles and aunts (3/106) and
nurses (2/106).
Table 1 Index case description
Total B. pertussis cases Negative cases
N = 199 N = 40 (20.1%) N = 159 (79.9%)
N (%) n (%) n (%) P value
Site
1 83 (41.7) 15 (37.5) 68 (42.8) 0.546
2 116 (58.3) 25 (62.5) 91 (57.2)
Gender
Boys 115 (57.8) 23 (60.0) 91 (57.2) 0.751
Girls 84 (42.8) 16 (40.0) 68 (42.8)
Age (months)
Median (IQR) 2.0 (1.3–2.8) 2.2 (1.4–2.9) 1.9 (1.2–2.8) 0.227
< 3 157 (79.9) 31 (77.5) 126 (79.3) 0.809
≥ 3 42 (21.1) 9 (22.5) 33 (20.7)
Pertussis immunization
Unknown 2 (0.0) 0 (0) 2 (0.0)
Non-vaccinated 124 (62.3) 20 (50.0) 104 (65.4) –
Age > 75 days 4 (3.2) 1 (5.3) 3 (2.9) 0.624
Vaccinated 73 (36.7) 20 (50.0) 53 (33.3) –
Booklet - 1 dose 58 (29.4) 17 (42.5) 41 (26.1) –
Booklet - 2 doses 12 (6.1) 1 (2.5) 11 (7.0) –
Booklet - 3 doses 2 (1.0) 1 (2.5) 1 (0.6) –
Declarative 1 (0.5) 1 (2.5) 0 (0) –
>> > Timeliness 71
Dose 1 68 (95.8) 19 (100) 49 (94.2) 0.285
Dose 2 14 (100) 2 (100) 12 (100) –
Dose 3 2 (100) 1 (100) 1 (100) –
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Table 2 Clinical description and antibiotic therapy of B. pertussis positive and negative index cases
N
available
Total B. pertussis cases Negative cases P
valuea
N = 199 N = 40 N = 159
Cough duration at inclusion (days)
median (IQR) 199 8 (6-11) 10 (7.5-19.5) 8 (6-10) 0.004
≥ 14 days n (%) 199 34 (17.1) 15 (37.5) 19 (12.0) <0.001
Pertussis-like symptoms
Nocturnal cough n (%) 199 104 (52.3) 22 (55.0) 82 (51.6) 0.698
Coughing spells n (%) 199 163 (81.9) 34 (85.0) 129 (81.1) 0.570
Apnea n (%) 199 31 (15.6) 9 (22.5) 22 (13.8) 0.177
Cyanosis n (%) 199 130 (65.3) 31 (77.5) 99 (62.3) 0.070
Inspiratory whoop n (%) 199 32 (16.1) 9 (22.5) 23 (14.5) 0.216
Difficult breathing in n (%) 199 83 (41.7) 17 (42.5) 66 (41.5) 0.910
Vomiting n (%) 199 49 (24.6) 10 (25.0) 39 (24.5) 0.951
Post tussif vomiting n (%) 199 57 (28.6) 16 (40.0) 41 (25.8) 0.076
Good conditions btw cough n (%) 197 139 (70.6) 24 (60.0) 115 (73.3) 0.101
Abnormal pulm auscultation n (%) 193 26 (13.5) 8 (21.1) 18 (11.6) 0.127
>> sign of upper infection n (%) 23 14 (60.9) 4 (50.0) 10 (66.7) 0.435
>> sign of lower infection n (%) 9 (39.1) 4 (50.0) 5 (33.3)
Temperature
≤ 37.5 n (%) 199 190 (95.5) 38 (95.0) 152 (95.6) 0.871
37.5-38.5 n (%) 9 (4.5) 2 (5.0) 7 (4.4)
Biological data
Leukocytes (/mm3) median (IQR) 191 10600 (8200-13200) 12900 (10100-17300) 9950 (7800-12400) <0.001
Lymphocytes (/mm3) median (IQR) 179 6640 (5150-9265) 10080 (6020-14245) 6438 (5073-8421) <0.001
Hyperlymphocytosis (> 9000/μl) n (%) 179 46 (25.7) 19 (54.3) 27 (18.8) <0.001
Neutrophiles (/mm3) median (IQR) 179 2772 (1900-4350) 3290 (1800-4862) 2662 (1944-4047) 0.495
Platelets (x103/mm3) median (IQR) 193 407 (304-506) 474 (320-605) 392 (297-485) 0.040
Hemoglobin (g/dl) median (IQR) 195 10.5 (9.8-11.5) 11 (9.9-11.6) 10.5 (9.7-11.5) 0.415
Mean corpuscular volume (MCV) (μ3) median (IQR) 194 87 (82-93) 87 (81-93) 87 (82.5-93) 0.567
SpO2 median (IQR) 196 95 (95-96) 95 (95-96) 95 (95-96) 0.856
Birth and weight
Premature birth (< 37 weeks) n (%) 197 22 (11.2) 2 (5.0) 20 (12.7) 0.165
Low birth weight (< 2.5 kg) n (%) 198 22 (11.1) 2 (5.0) 20 (12.7) 0.169
Wasting n (%) 188 54 (28.7) 13 (34.2) 41 (27.3) 0.403
Stunting n (%) 196 23 (11.7) 6 (15.0) 17 (10.9) 0.472
Antibiotic therapy before enrollment
Yes n (%) 188 120 (63.8) 24 (63.2) 96 (64.0) 0.923
Macrolides n (%) 82 (43.6) 16 (42.1) 66 (44.0) 0.833
>> for > 48h before sampling n (%) 82 37 (45.1) 10 (62.5) 27 (40.9) 0.119
Last clinical evaluation
Time after inclusion (days) median (IQR) 195 14 (13-14) 14 (13-14) 14 (13-14) 0.933
Full recovery n (%) 195 164 (84.1) 27 (67.5) 137 (88.4) 0.002
Healing with persistent cough n (%) 195 27 (13.9) 10 (25.0) 17 (11.0) -
No improvement n (%) 195 2 (1.0) 2 (5.0) 0 (0-) -
Death n (%) 195 2 (1.0) 1 (2.5) 1 (0.7) -
Hospitalization
Yes n (%) 199 192 (96.5) 39 (97.5) 153 (96.2) 0.696
aP values in bold indicate p < 0.05
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Pertussis diagnosis
A total 104/106 contact cases had a final diagnosis.
Pertussis infection was confirmed for 53/104 (51.0%)
contact cases by qPCR (36/104), serology (9/104) or
both (8/104) (Table 3). Negative biological confirmation
was obtained for 51/104 (49.0%) contacts. One B. pertus-
sis was isolated by culture, no B. holmesii and no B.
parapertussis were detected either by qPCR or culture
among contacts.
B. pertussis positive contact cases were mostly adults
(75.5%) with median age of 31 years, ranging 2 to 59
years old (Table 3). They included mothers (34.0%), fa-
thers (32.1%), < 10 years old siblings (17.0%), ≥ 10 years
old siblings (7.6%), grandfathers and grandmothers
(5.7%) and nurses (3.8%) (Table 3).
Pertussis vaccination history
Among siblings aged < 10 years who were tested positive
(9/53), 100% were confirmed B. pertussis positive by
qPCR, regardless of their serology result, and had cough.
No information was obtained regarding the date of their
last pertussis vaccination. However, 2/9 aged 8 and 9
years reported to be not vaccinated, and 7/9 were vacci-
nated with 4 doses but did not receive the 5th dose yet
(they were 2, 6, 7 and 8 years old) or with unknown
number of dose (they were 3, 3 and 5 years old).
Clinical assessment
Contact cases did not report symptoms (15/53), were
symptomatic with cough onset reported during the study
(2/53), or symptomatic with reported cough at inclusion
(36/53).
Among the 15 asymptomatic contact cases, B. pertussis
was detected by qPCR (12/15), by serology (2/15), or by
both assays (1/15) (Table 3). Regarding the use of
macrolide antibiotics, 2/15 had a treatment (azithromy-
cin) before inclusion (4 and 9 days), which may have in-
terfered with cough onset. For 5/15 contacts the use of
any macrolide antibiotics was not known while 8/15 did
not receive any treatment. Asymptomatic contact cases
included 13/15 fathers and mothers, 1/15 grandmother
and 1/15 twelve-years-old sister.
Table 3 Pertussis positive contact case description
Total Asymptomatic Symptomatic at inclusion Symptomatic during study
N = 53 N = 15 (28.3%) N = 36 (67.9%) N = 2 (3.8%)
Age
median (IQR) 31 (18-36) 31 (24-35) 30.5 (10.5-36) 46.5
min-max 2-59 12-57 2-59 41-52
Relationship with index
Mothers n (%) 18 (34.0) 6 (40.0) 12 (33.4) 0 (0)
Fathers n (%) 17 (32.1) 7 (46.7) 9 (25.0) 1 (50.0)
Siblings (<10 yoa) n (%) 9 (17.0) 0 (0) 9 (25.0) 0 (0)
Siblings (≥10 yoa) n (%) 4 (7.6) 1 (6.7) 3 (8.3) 0 (0)
Gdfathers/Gdmothersb n (%) 3 (5.7) 1 (6.7) 1 (2.8) 1 (50.0)
Nurses n (%) 2 (3.8) 0 (0) 2 (5.6) 0 (0)
Pertussis diagnosis
PCR+ only n (%) 36 (67.9) 12 (80.0) 22 (61.1) 2 (100)
Serology+ only n (%) 9 (17.0) 2 (13.3) 7 (19.4) 0 (0)
PCR+ and serology+ n (%) 8 (15.1) 1 (6.7) 7 (19.4) 0 (0)
Pertussis vaccination history
Siblings <10 yo* n 9 0 9 0
Non-vaccinated n (%) 2 (22.2) - 2 (22.2) -
Vaccinated n (%) 7 (77.8) - 7 (77.8) -
>> unknown doses n (%) 3 (42.9) - 3 (42.9) -
>> 4 doses n (%) 4 (57.1) - 4 (57.1) -
Macrolide treatment before inclusion
No n (%) 26 (49.1) 8 (53.3) 17 (42.2) 1 (50.0)
Yes n (%) 17 (32.1) 2 (13.3) 14 (38.9) 1 (50.0)
Unknown n (%) 10 (18.9) 5 (33.3) 5 (13.9) 0 (0)
ayo years old, bgdfathers/gdmothers grandfathers / grandmothers
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Contacts who reported cough onset during the study
(2/53) were confirmed positive by qPCR and were nega-
tive by serology.
There were 36/53 contact cases presenting cough at
inclusion, they included all the pertussis positive contact
aged < 10 years. Nocturnal cough (42.9%), coughing
spells (45.7%) and good condition between cough
(57.1%) were mainly reported (Table 4).
Source of infection
Symptomatic contact cases (38/53) were further classi-
fied as primary or secondary cases based on the time of
cough onset. There were 11/53 (20.8%) contact cases
identified as potential primary cases, they were all
coughing for more than 20 days at index cough onset
(Fig. 2a). A single primary case was identified for five
index cases; there were a nurse (n = 1), a 12-year-old sib-
ling who declared to be vaccinated (n = 1), and the
mother (n = 3). For two index cases, several potential
source of infection were identified and included the
mother, the father and two non-vaccinated siblings aged
8 and 9 years, and the mother and a 14-year-old brother
who had received four doses of pertussis vaccine during
infancy only.
Twenty-seven symptomatic (50.9%) contact cases
contracted pertussis infection along or after the infants
(Fig. 2b).
Discussion
This prospective hospital-based study shows that B. per-
tussis infection was confirmed in 20.1% (40/199) of the
infants presenting ≥5 days of cough associated to one
pertussis-like symptom enrolled in two main hospitals in
Tehran, and highlights the high circulation of the patho-
gen among their contacts aged 2 to 59 years old.
In infants, clinical and biological evaluation evidenced
that higher number of leukocytes, lymphocytes, platelets
and cough duration were significantly associated to per-
tussis infection. While the relationship between platelets
and pertussis is controversial, the association of white
blood cell number and cough duration with pertussis
was previously described in Iran and in other settings,
including in HIC [19, 20]. Of note, we observed that
62.5% of the confirmed positive infants coughed less
than 14 days when seeking diagnosis. However, add-
itional symptoms typically associated to pertussis (i.e.
nocturnal or coughing spells, apnea, cyanosis, inspiratory
whoop, difficulty breathing in, post-tussif vomiting) were
not found to be more frequent in infants with pertussis
in this study. As expected, absence of fever and normal
pulmonary auscultation were mainly reported among
pertussis positive infants, nevertheless it was not specif-
ically associated to positivity either. A recent study in
Italy developed an algorithm based on clinical symptoms
to predict pertussis infection, however, although it may
be a good predictor when using local data, our results
highlighted that qPCR testing is indispensable for per-
tussis diagnosis [21].
A National Pertussis Reference laboratory is estab-
lished in Tehran, but only a few samples collected from
different areas of the country are sent to that laboratory
for biological testing [8]. Given the difficulty of clinically
diagnosing pertussis, biological diagnosis should be more
widely used for National surveillance. It is particularly
important as its sensitivity has greatly improved with the
use of qPCR targeting the IS481 sequence that is present
at a high copy number within B. pertussis’ genome. In
fact, while only five samples were successfully cultured
during this study, 84 cases were confirmed as pertussis
positive by qPCR. The use of macrolide antibiotics a few
days before sampling, the presence of Amies buffer as
sample transport media, or the delay for culturing sam-
ple that was sometimes up to 24 h may have impaired
culture. Nevertheless, when samples contain low quan-
tity of target, IS481 amplification may be low (CT > 35)
and sample might be interpreted as negative as fixed
positive diagnosis threshold is commonly defined as
CT ≤ 35. However, Gill and colleagues recently showed
how the burden of pertussis may be substantially under-
estimated when restricting diagnostic criteria to IS481
CT ≤ 35 [17]. Herein, correlating with Gill et al., we
identified 6 index cases having IS481 CT > 35 but for
whom up to four of the respective contact cases exhib-
ited B. pertussis confirmed qPCR and/or serology. How-
ever, in absence of epidemiological confirmation or
repeated nasopharyngeal sampling over time, uncertainty
remains on the positivity of the sample [17]. In addition,
for research purposes, amplification of specific se-
quences (such as ptxp, IS1002, hIS1001) are needed to
Table 4 Clinical assessment of symptomatic contact cases at
inclusion
Symptoms reported at inclusion N = 36
Duration of cough (days) median (IQR) 17.5 (9–32)
≥ 7 n (%) 31 (86.1)
≥ 14 n (%) 20 (55.6)
Nocturnal cough a n (%) 15 (42.6)
Coughing spells a n (%) 16 (45.7)
Apnea a n (%) 0 (0)
Cyanosis a n (%) 0 (0)
Inspiratory whoop a n (%) 1 (2.9)
Difficult breathing in a n (%) 3 (8.6)
Vomiting a n (%) 0 (0)
Post tussif vomiting a n (%) 1 (2.9)
Good conditions btw cough a n (%) 20 (57.1)
a n = 1 with no information available
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confirm B. pertussis species among IS481+ samples, se-
quence also present in B. holmesii genome, but not al-
ways possible as those sequences are present at a single
or low copy number within bacterial genome [22].
In this study, although all infants aged 0–6 months old
exhibiting pertussis-like syndrome were considered, en-
rolled infants were mostly less than 3 months of age
(80%) and were either non-vaccinated or had received a
single dose (> 90%). To prevent severe pertussis cases in
infants, WHO recommended that every country should
seek to achieve early and timely vaccination initiated at
6 weeks of age and no later than 8 weeks [3]. Only 4 in-
fants were late in starting the vaccination program
among the 199 participating infants, and > 90% of those
infants who were vaccinated complied with the national
vaccination schedule in this study. Compliance with vac-
cination schedule was also found to be very good among
vaccinated children 3–15 years old in Tehran, confirming
our data [10]. Timeliness may nevertheless vary through-
out the country as high incidence of delayed vaccination
was reported in the outskirt of Iran’s big cities [23].
Due to the arrangement of family unit in Tehran, only
a few numbers of contact cases were included and sev-
eral index case had no or few contacts. Among the 39
infants for whom contacts were tested, 33 had at least
one contact with a confirmed B. pertussis infection.
Overall, more than half of the contact cases were tested
positive for pertussis infection. All age groups were con-
cerned and median age was 31 years old. Parents were
more frequently tested as positive contact (66.0%),
followed by siblings (24.5%). This relationship with in-
fant and age distribution of primary case contacts was
recently shown to be similar in HIC where aPVs are
used [24]. The important rate of pertussis infection
among contact cases observed herein highlights the
underreporting among older children and adults and are
in line with studies evidencing substantial circulation of
pertussis among Iranian children and adolescents [10,
25]. In addition, although all positive children presented
symptoms, more than 30% of older individuals did not
recall having or did not have cough at any time during
the study. When cough was reported, there was no add-
itional symptom, as often reported in pertussis-infected
adults [26, 27]. In this study 11 possible primary cases
were identified who were contacts of 7/39 (17.9%) posi-
tive infants. More than 90% were household contacts
(mothers, siblings and father represented 5/11, 4/11, 1/
11, respectively). The Wiley et al.’s systematic review
demonstrated that, when identified, the source of infec-
tion in infants aged < 6months in HIC were household
contacts in 74–96% of the cases, parents being identified
more often, which is in agreement with our findings
[28]. Similar observations were found in Brazil [29].
Identification of primary cases was limited. This is due
to a lack of awareness of the disease among the general
population that impairs identification and report of per-
tussis symptoms, and to possible subclinical infections.
In addition, no symptom typically associated to pertus-
sis, except duration of cough, was found to be associated
to a positive molecular diagnosis result of pertussis in in-
fants. This could be related to a lack of power of our
study.
In Iran, the implementation of adolescent booster vac-
cine, which would contribute to increasing herd immun-
ity, was proposed and expected to be cost-effective [30,
31]. Another complementary strategy would be the
introduction of maternal immunization, found to be ef-
fective around the world including in LMIC, which
would contribute to reducing the rate of severe and fatal
cases among the newborns [3, 32–35].
Conclusions
This study evidences substantial prevalence of B. pertus-
sis among infants exhibiting cough and among their
close contacts. It also shows that biological testing is
crucial for diagnosis in infants for whom clinical symp-
toms are poorly specific, and in contacts who are poorly
symptomatic and/or not aware of pertussis symptoms.
Sensitive and specific diagnosis tool such as qPCR
should be widely used for surveillance.
Fig. 2 Distribution of primary (a) and secondary (b) cases with respect to the index case among positive contacts. yo, years old
Noel et al. BMC Infectious Diseases          (2021) 21:586 Page 9 of 11
Abbreviations
LMIC: Low and middle-income countries; wPV: Whole-cell vaccine; HIC: High-
income countries; aPV: Acellular vaccine; qPCR: Real-time quantitative
polymerase chain reaction; PT: Pertussis toxin; IgG: Immunoglobulin G;
ELISA: Enzyme-linked immunosorbent assay; WHO: World Health
Organization; NIBSC: National Institute for Biological Standards and Control;
IU: International units; LLOQ: Lower limit of quantitation; CT: Cycle threshold;
IQR: Interquartile range; yo: Years old; gdfathers/gdmothers: Grandfathers /
grandmothers
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12879-021-06266-6.
Additional file 1: Figure S1. Decision tree flowchart for Bordetella
species identification for biological diagnosis using qPCR assays.
Additional file 2: Table S1. Primer and probe sequences for TaqMan
technology-based real time PCR assays.
Acknowledgments
We thank all the children and their parents or legal guardians for
participating to this study. We also thank Sandra Corre for her participation
in implementing the study and laboratory staff training and Vajihe S. Nibkin
for her support in data cleaning.
Authors’ contributions
NG, FT, MAA, FS, SMZ contributed to the Study design. RMG, TH, AG, AKaz,
AKar, AN, FS, SMZ participated in investigation and sample collection. MNL,
SMi, SMa performed sample analyses. GN, DT, MNL, SMi ensured data
curation. FT, NG, FS, GN supervised the activities. GN, NG, FT contributed to
formal analysis. GN and NG wrote the original draft, and all authors revised
the manuscript and agreed with its submission to the journal.
Funding
This study was funded by the Institut Pasteur, Paris. Donation from the Clara
Belliveau Foundation also supported this work.
Availability of data and materials
The datasets used and/or analyzed during the current study are available as
de-identified, from the corresponding author on reasonable request.
Declarations
Ethics approval and consent to participate
The study was conducted under the sponsorship of the Institut Pasteur of
Iran. The study protocol was performed in accordance with the Declaration
of Helsinki, and was reviewed and approved by the Research Ethics
Committee of Pasteur Institute of Iran (reference n° IR.PII.REC.1394.24).
Informed written consent was obtained from both the adult participants and
the parent(s)/legal guardian(s) of all under-18 s (minor children), and oral
consent form was obtained from children aged over 7 years. Only individuals
who agreed to participate were included in the study. Authorization for data
processing has been obtained from French legal authority (Commission
Nationale Informatique et Liberté [CNIL]), and pseudonymization of names




The authors have declared that no conflict of interests exist.
Author details
1Center for Translational Science, Institut Pasteur, Paris, France. 2Department
of Bacteriology, Pertussis Reference Laboratory, Pasteur Institute of Iran,
Tehran, Islamic Republic of Iran. 3Emerging Diseases Epidemiology unit,
Institut Pasteur, Paris, France. 4Center for Communicable Diseases Control,
Ministry of Health and Medical Education, Tehran, Islamic Republic of Iran.
5Pediatric Infections Research Center, Mofid Children’s Hospital, Shahid
Beheshti University of Medical Sciences, Research Institute for Children’s
Health, Tehran, Islamic Republic of Iran. 6Department of Pediatrics, Ali Asghar
children hospital, Iran University of Medical Sciences, Tehran, Islamic Republic
of Iran. 7Pediatric cardiology department, Mofid Children’s Hospital, Shahid
Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.
8Emergency Department, Mofid Children’s Hospital, Shahid Beheshti
University of Medical Sciences, Tehran, Islamic Republic of Iran. 9Centre for
Translational Science, Clinical Coordination, Institut Pasteur, Paris, France.
10Department of International Affairs, Institut Pasteur, Paris, France.
Received: 5 March 2021 Accepted: 1 June 2021
References
1. Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW. An update of the global
burden of pertussis in children younger than 5 years: a modelling study.
Lancet Infect Dis. 2017;17(9):974–80. https://doi.org/10.1016/S1473-3099(17)3
0390-0.
2. World Health Organization. Pertussis vaccines: WHO position paper. Wkly
Epidemiol Rec 2010. 2010;85:385–400.
3. World Health Organization. Pertussis vaccines: WHO position paper. Wkly
Epidemiol Rec 2015. 2015;90:433–58.
4. von Koenig CHW, Guiso N. Global burden of pertussis: signs of hope but
need for accurate data. Lancet Infect Dis. 2017;17(9):889–90. https://doi.
org/10.1016/S1473-3099(17)30357-2.
5. WHO UNICEF estimates time series for Iran (Islamic Republic of) (IRN). WHO
vaccine-preventable diseases: monitoring system. 2020 global summary.
Available from: https://apps.who.int/immunization_monitoring/globa
lsummary/estimates?c=IRN. Accessed 30 Oct 2020.
6. World Health Organization: Incidence time series for Iran (Islamic Republic
of) (IRN). WHO vaccine-preventable diseases: monitoring system. 2020
global summary. Available from: https://apps.who.int/immunization_
monitoring/globalsummary/incidences?c=IRN. Accessed 30 Oct 2020.
7. Safarchi A, Octavia S, Nikbin VS, Lotfi MN, Zahraei SM, Tay CY, et al.
Genomic epidemiology of Iranian Bordetella pertussis: 50 years after the
implementation of whole cell vaccine. Emerg Microbes Infect. 2019;8(1):
1416–27. https://doi.org/10.1080/22221751.2019.1665479.
8. Sedaghat M, Nakhost Lotfi M, Talebi M, Saifi M, Pourshafie MR. Status of
pertussis in Iran. Jundishapur J Microbiol. 2014;7(11):e12421. https://doi.
org/10.5812/jjm.12421.
9. Khazaei S, Ayubi E, Mansori K, Khazaei S. Pertussis incidence by time, province
and age Group in Iran, 2006-2011. Iran J Public Health. 2016;45(11):1525–7.
10. Noel G, Badmasti F, Nikbin VS, Zahraei SM, Madec Y, Tavel D, et al. Transversal
sero-epidemiological study of Bordetella pertussis in Tehran, Iran. PLoS One.
2020;15(9):e0238398. https://doi.org/10.1371/journal.pone.0238398.
11. Ghanaie RM, Karimi A, Sadeghi H, Esteghamati A, Fallah F, Armin S, et al.
Frequency of pertussis in iranian school-age children. J Pediatr Infect Dis.
2013;08(01):001–5.
12. World Health Organization: Laboratory manual for the diagnosis of
whooping cough caused by Bordetella pertussis/Bordetella parapertussis. In.
Edited by WHO/IPV/14.03; 2014.
13. Riffelmann M, Wirsing von König CH, Caro V, Guiso N, for the Pertussis PCRCG.
Nucleic acid amplification tests for diagnosis of Bordetella infections. J Clin
Microbiol. 2005;43(10):4925–9. https://doi.org/10.1128/JCM.43.10.4925-4929.2005.
14. Katfy K, Guiso N, Diawara I, Zerouali K, Slaoui B, Jouhadi Z, et al.
Epidemiology of pertussis in Casablanca (Morocco): contribution of
conventional and molecular diagnosis tools. BMC Infect Dis. 2017;17(1):348.
https://doi.org/10.1186/s12879-017-2452-3.
15. Njamkepo E, Bonacorsi S, Debruyne M, Gibaud SA, Guillot S, Guiso N.
Significant finding of Bordetella holmesii DNA in nasopharyngeal samples
from French patients with suspected pertussis. J Clin Microbiol. 2011;49(12):
4347–8. https://doi.org/10.1128/JCM.01272-11.
16. Riffelmann M, Thiel K, Schmetz J, Wirsing von Koenig CH. Performance of
commercial enzyme-linked Immunosorbent assays for detection of
antibodies to Bordetella pertussis. J Clin Microbiol. 2010;48(12):4459–63.
https://doi.org/10.1128/JCM.01371-10.
17. Gill CJ, Gunning CE, MacLeod W, Mwananyanda L, Thea D, Pieciak R, et al.
Asymptomatic Bordetella pertussis infections in young African infants and
their mothers identified within a longitudinal cohort. medRxiv : the preprint
server for health sciences, 2020.11.18.20231423. https://doi.org/10.1101/202
0.11.18.20231423. Preprint.
Noel et al. BMC Infectious Diseases          (2021) 21:586 Page 10 of 11
18. World Health O. WHO child growth standards : length/height-for-age, weight-
for-age, weight-for-length, weight -for-height and body mass index-for-age :
methods and development. Geneva: World Health Organization; 2006.
19. Shojaei J, Saffar M, Hashemi A, Ghorbani G, Rezai M, Shahmohammadi S.
Clinical and laboratory features of pertussis in hospitalized infants with
confirmed versus probable pertussis cases. Ann Med Health Sci Res. 2014;
4(6):910–4. https://doi.org/10.4103/2141-9248.144911.
20. Muloiwa R, Nicol MP, Hussey GD, Zar HJ. Diagnostic limitations of clinical
case definitions of pertussis in infants and children with severe lower
respiratory tract infection. PLoS One. 2020;15(7):e0235703. https://doi.org/1
0.1371/journal.pone.0235703.
21. Tozzi AE, Gesualdo F, Rizzo C, Carloni E, Russo L, Campagna I, et al. A data
driven clinical algorithm for differential diagnosis of pertussis and other
respiratory infections in infants. PLoS One. 2020;15(7):e0236041. https://doi.
org/10.1371/journal.pone.0236041.
22. Loeffelholz M. Towards improved accuracy of Bordetella pertussis nucleic
acid amplification tests. J Clin Microbiol. 2012;50(7):2186–90. https://doi.
org/10.1128/JCM.00612-12.
23. Rejali M, Mohammadbeigi A, Mokhtari M, Zahraei SM, Eshrati B. Timing and
delay in children vaccination; evaluation of expanded program of
immunization in outskirt of Iranian cities. JRHS. 2015;15(1):54–8.
24. Merdrignac L, Aït El Belghiti F, Pandolfi E, Jané M, Murphy J, Fabiánová K,
et al. Incidence and severity of pertussis hospitalisations in infants aged less
than 1 year in 37 hospitals of six EU/EEA countries, results of PERTINENT
sentinel pilot surveillance system, December 2015 to December 2018. Euro
Surveill. 2021;26(4):1900762.
25. Ghanaie RM, Karimi A, Sadeghi H, Esteghamti A, Falah F, Armin S, et al.
Sensitivity and specificity of the World Health Organization pertussis clinical
case definition. Int J Infect Dis. 2010;14(12):e1072–5. https://doi.org/10.1016/
j.ijid.2010.07.005.
26. Siriyakorn N, Leethong P, Tantawichien T, Sripakdee S, Kerdsin A, Dejsirilert
S, et al. Adult pertussis is unrecognized public health problem in Thailand.
BMC Infect Dis. 2016;16:25.
27. Barkoff A-M, Gröndahl-Yli-Hannuksela K, He Q. Seroprevalence studies of
pertussis: what have we learned from different immunized populations.
Pathog Dis. 2015;73(7):ftv050.
28. Wiley KE, Zuo Y, Macartney KK, McIntyre PB. Sources of pertussis infection in
young infants: a review of key evidence informing targeting of the cocoon
strategy. Vaccine. 2013;31(4):618–25. https://doi.org/10.1016/j.vaccine.2012.11.052.
29. Baptista PN, Magalhães V, Rodrigues LC, Rocha MÂW, Pimentel AM. Source
of infection in household transmission of culture-confirmed pertussis in
Brazil. Pediatr Infect Dis J. 2005;24(11):1027.
30. Esposito S, Principi N. Immunization against pertussis in adolescents and
adults. Clin Microbiol Infect. 2016;22:S89–95. https://doi.org/10.1016/j.cmi.2
016.01.003.
31. Mansour Ghanaie R, Moradi-Lakeh M, Karimi A, Yaghoubi M, Amiraslany A,
Gill A, et al. Future strategic plan for national immunisation program in Iran:
cost effectiveness of acellular pertussis versus whole-cell. Int J Foresight
Innov Policy. 2018;13(1/2):136. https://doi.org/10.1504/IJFIP.2018.095865.
32. Romanin V, Acosta AM, Juarez MDV, Briere E, Sanchez SM, Cordoba BL, et al.
Maternal vaccination in Argentina: tetanus, diphtheria, and Acellular
pertussis vaccine effectiveness during pregnancy in preventing pertussis in
infants <2 months of age. Clin Infect Dis. 2020;70(3):380–7. https://doi.org/1
0.1093/cid/ciz217.
33. De Barros ENC, Nunes AA, Abreu AJL, Furtado BE, Cintra O, Cintra MA, et al.
Pertussis epidemiological pattern and disease burden in Brazil: an analysis
of national public health surveillance data. Hum Vaccin Immunother. 2020;
16(1):61–9. https://doi.org/10.1080/21645515.2019.1634991.
34. Hincapié-Palacio D, Hoyos MC, Ochoa J, Montoya N, García D, Osorio E.
Effect of maternal immunization against pertussis in Medellin and the
metropolitan area, Colombia, 2016–2017. Vaccine. 2018;36(27):3984–91.
https://doi.org/10.1016/j.vaccine.2018.05.020.
35. Switzer C, D'Heilly C, Macina D. Immunological and clinical benefits of
maternal immunization against pertussis: a systematic review. Infect Dis
Ther. 2019;8(4):499–541. https://doi.org/10.1007/s40121-019-00264-7.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Noel et al. BMC Infectious Diseases          (2021) 21:586 Page 11 of 11
